These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 18773966

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R.
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [Abstract] [Full Text] [Related]

  • 4. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C, Lyko F.
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
    Swaminathan V, Reddy BA, Ruthrotha Selvi B, Sukanya MS, Kundu TK.
    Subcell Biochem; 2007 Nov; 41():397-428. PubMed ID: 17484138
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
    Schneider-Stock R, Ocker M.
    IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Epigenetic alterations and cancer: new targets for therapy.
    Allen A.
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [Abstract] [Full Text] [Related]

  • 13. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
    Vaissière T, Sawan C, Herceg Z.
    Mutat Res; 2008 Oct; 659(1-2):40-8. PubMed ID: 18407786
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. HDAC inhibitors: clinical update and mechanism-based potential.
    Glaser KB.
    Biochem Pharmacol; 2007 Sep 01; 74(5):659-71. PubMed ID: 17498667
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM.
    Expert Rev Anticancer Ther; 2007 Oct 01; 7(10):1439-49. PubMed ID: 17944568
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Epigenome: a new target in cancer therapy.
    Giacinti L, Vici P, Lopez M.
    Clin Ter; 2008 Oct 01; 159(5):347-60. PubMed ID: 18998037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.